UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934:
For quarterly period ended March 31, 2003
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934:
For the transition period from ___________ to _______________
Commission File Number: 038593
CAPITAL PARTNERS II, LTD. LIQUIDATING TRUST
(Successor in interest to Renaissance Capital Partners II, Ltd.)
______________________________________________________________________________
(Exact name of registrant as specified in its charter)
Texas 75-6590369
______________________________________________________________________________
(State or other jurisdiction (IRS Employer ID No.)
of incorporation or organization)
5646 Milton Street, Suite 900, Dallas TX 75206
______________________________________________________________________________
(Address of principal executive offices) (Zip code)
(214) 378-9340
______________________________________________________________________________
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. Yes [X] No [ ]
PART I. FINANCIAL INFORMATION
ITEM 1: FINANCIAL STATEMENTS
CAPITAL PARTNERS II, LTD. LIQUIDATING TRUST
(Successor to Renaissance Capital Partners II, Ltd.)
STATEMENTS OF ASSETS AND LIABILITIES
(Unaudited)
Assets
December 31, March 31,
2002 2003
___________ ___________
<s> <c> <c>
Cash $ 51,201 $ 34,360
Investments at fair value,
cost of $16,348,874 at December 31, 2002,
and March 31, 2003 12,124,401 9,185,153
_____________ _____________
Total Assets $ 12,175,602 $ 9,219,513
============= =============
Liabilities
Liabilities:
Accounts Payable and Accrued Expenses $ 78 606 $ 86,688
Note Payable (see note 5) 50,000 50,000
_____________ _____________
Total liabilities 128,606 136,688
_____________ _____________
Net Assets in Liquidation 12,046,996 9,082,825
_____________ _____________
$ 12,175,602 $ 9,219,513
============= =============
Net Assets in Liquidation per Unit
of Beneficial Interest $601 $453
==== ====
Number of Units of Beneficial
Interest Outstanding 20,054 20,054
====== ======
See accompanying notes to financial statements.
CAPITAL PARTNERS II, LTD. LIQUIDATING TRUST
(Successor to Renaissance Capital Partners II, Ltd.)
STATEMENTS OF OPERATIONS
(Unaudited)
Three Months Ended March 31,
2002 2003
_________ __________
<s> <c> <c>
Income -
Interest income $ -0- $ 98
____________ ____________
-0- 98
____________ ____________
Expenses -
Interest expense 4,318 1,233
General and administrative 30,976 23,787
Trustee Fees 18,000 -0-
____________ ____________
Total Expenses 53,294 25,020
____________ ____________
Net operating loss (53,294) (24,922)
____________ ____________
Net unrealized appreciation (depreciation)
on investments 15,275,868 (2,939,249)
____________ ____________
Net increase (decrease) in net assets
from operations $ 15,222,574 $ (2,964,171)
============ ============
See accompanying notes to financial statements.
CAPITAL PARTNERS II, LTD. LIQUIDATING TRUST
(Successor to Renaissance Capital Partners II, Ltd.)
STATEMENTS OF CHANGES IN NET ASSETS IN LIQUIDATION
(Unaudited)
Three Months Ended March 31,
2002 2003
________ ________
<s> <c> <c>
Change in net assets resulting from
operations:
Net operating loss $ (53,294) $ (24,922)
Change in net unrealized appreciation or
depreciation of portfolio investments 15,275,868 (2,939,249)
Change in net assets resulting from
contributions to corpus 179,437 -0-
____________ ____________
Net increase (decrease) in net assets
for the period 15,402,011 (2,964,171)
Net assets in liquidation at beginning
of period 23,349,052 12,046,996
____________ ____________
Net assets in liquidation at end
of period $ 38,751,063 $ 9,082,825
============ ============
See accompanying notes to financial statements.
CAPITAL PARTNERS II, LTD. LIQUIDATING TRUST
(Successor to Renaissance Capital Partners II, Ltd.)
STATEMENTS OF CASH FLOWS
(Unaudited)
Three Months Ended March 31,
2002 2003
________ ________
<s> <c> <c>
Cash flows from operating activities
Net increase (decrease) in net assets
from operations $ 15,222,574 $ (2,964,171)
Adjustments to reconcile net assets
from operations to net cash used
in operating activities:
Net unrealized (appreciation)
depreciation on investments (15,275,868) 2,939,249
Increase (decrease) in accounts
payable and accrued liabilities (9,673) 8,081
Decrease (increase) in assets (6,459) -0-
_____________ _____________
Net cash used in operating activities (69,426) (16,841)
Cash flows from financing activities
Contributions to corpus 49,903 -0-
_____________ _____________
Net cash provided from financing activities 49,903 -0-
_____________ _____________
Net increase (decrease) in cash and
cash equivalents (19,523) (16,841)
Cash and cash equivalents at
beginning of period 19,641 51,201
_____________ _____________
Cash and cash equivalents at
end of period $ 118 $ 34,360
============= =============
Supplemental disclosure of cash flow information:
Interest paid $ -0- $ 1,411
============= =============
Supplemental disclosure of noncash transactions:
Note payable and accrued interest
contributed to corpus $ 129,533 $ -0-
============= =============
See accompanying notes to financial statements.
CAPITAL PARTNERS II, LTD. LIQUIDATING TRUST
(Successor to Renaissance Capital Partners II, Ltd.)
Notes to Financial Statements
March 31, 2003
1. Organization and Purpose
Capital Partners II, Ltd. Liquidating Trust (the "Trust"), a liquidating
trust established under the laws of the State of Texas on November 17, 2000,
is the successor entity to Renaissance Capital Partners II, Ltd. (the
"Partnership"). Pursuant to the Liquidating Trust Agreement, the Trust was to
terminate no later than November 17, 2002. The Partnership, which was a Texas
limited partnership formed in 1991, was organized as a diversified, closed-end
management investment partnership and operated as a business development
company under the Investment Act of 1940. The Partnership's investment
objective was to achieve current income and capital appreciation potential by
investing primarily in private placement convertible debt investments of small
and medium size companies which the Managing General Partner believed offered
the opportunity for growth. On October 1, 1998, the Managing General Partner
and the Independent General Partners agreed to commence liquidation of the
Partnership. The Managing General Partner withdrew from the Partnership and
the Partnership appointed an independent general partner as Liquidation
Trustee (the "Trustee"). The Trustee, pursuant to a Liquidation Trustee
Agreement, assumed all responsibilities and has the authority of the Managing
General Partner.
On November 17, 2000, the limited partners of the Partnership authorized the
Trustee to transfer the investment assets of the Partnership to the Trust.
Upon formation of the Trust and transfer of investment assets to the Trust,
holders of the 43,254 limited partnership units of the Partnership,
outstanding on November 17, 2000, were deemed to become holders of 43,254
units of beneficial interest in the Trust ("Units").
On November 4, 2002, the Trustee amended the Trust to extend the term for
one year to November 17, 2003. Beneficiaries were given the option to elect
out of the Trust and receive their proportionate interests in the Trust's
single remaining portfolio investment, shares of common stock of Tutogen
Medical, Inc. ("Tutogen"). 120 beneficiaries elected to withdraw prior to the
deadline of December 19, 2002. The Trust distributed 4,230,847 shares of
Tutogen common stock to the withdrawing beneficiaries, of which Centerpulse
USA Holding Co. (formerly known as Sulzer Medica USA Holding Co.) accounted
for 3,952,454 shares withdrawing from the Trust.
As of December 31, 2002, the Trustee transferred the remaining cash out of
the partnership into the Trust. As the Partnership has no remaining assets,
it dissolved as of December 31, 2002. All of the Tutogen shares are held in
the Trust.
2. Significant Accounting Policies
(a) Valuation of Investments
Portfolio investments are carried at fair value as determined quarterly by the
Trustee. The fair value of each publicly-held portfolio security is adjusted
to the closing public market price on the last day of the calendar quarter.
Most securities held by the Trust are thinly traded and their value as of a
particular date does not necessarily represent the amounts that may be
realized from their immediate sale or disposition.
(b) Federal Income Taxes
The Trust is a pass-through entity for federal income tax purposes and,
accordingly, is not subject to income tax. Instead, each beneficiary of the
Trust is required to take into account, in accordance with such beneficiary's
method of accounting, such beneficiary's pro rata share of the Trust's income,
gain, loss, deduction or expense, regardless of the amount or timing of
distributions to beneficiaries.
(c) Management Estimates
The preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and
the reported amounts of revenues and expenses during the reporting period.
Actual results could differ from those estimates.
3. Basis of Presentation
The accompanying financial statements have been prepared without audit, in
accordance with the rules and regulations of the Securities and Exchange
Commission and include all disclosures normally required by accounting
principles generally accepted in the United States of America, but do not
include all disclosures normally made in annual reports on Form 10-K. All
material adjustments, consisting only of those of a normal recurring nature,
which, in the opinion of management, were necessary for a fair presentation of
the results for the interim period have been made.
4. Trustee and Management Fees
In 1998, the Partnership entered into an agreement with the Trustee, whereby
the Trustee provided management services to the Partnership in connection with
its liquidation and has continued to provide such services to the Trust during
its liquidation. For services rendered under the agreement, the Trustee
receives $6,000 per month plus up to $4,000 per month for reimbursement of
administrative personnel. Effective January 1, 2003, the Trustee has deferred
his compensation of $6,000 per month and will be paid only if the value of
Tutogen stock has increased by 50% or more above the closing price of $2.65,
based on the market price when the Trust is terminated or the price realized
by the Trust from a sale of Tutogen common stock, if such sale occurs before
the termination of the Trust.
The Trustee serves as Chairman of the Board of Tutogen Medical, Inc., a
portfolio investment of the Trust, and the Trustee is the beneficial owner of
178,040 shares of common stock of Tutogen Medical, Inc. with stock options to
purchase an additional 140,000 shares of common stock.
5. Note Payable
On December 19, 2002, the Trust entered into a Loan Agreement with Garvon,
Inc. Profit Sharing Plan ("Garvon"). Garvon is the holder of 9 units of
beneficial interest in the Trust. Garvon agreed to loan the Trust up to
$100,000 in two instalments of $50,000 with collateral up to 500,000 shares of
Tutogen common stock. The loan bears interest at the rate of 10%, payable
quarterly and is due on December 19, 2003. At December 31, 2002, the Trust
had borrowed $50,000, collateralized with 250,000 shares of Tutogen common
stock. The proceeds of the loan were used to provide working capital for the
Trust.
On March 31, 2003, the Trust paid interest accrued on this note to Garvon in
the amount of $1,411.
6. Investments
Investments of the Trust are carried in the statements of assets,
liabilities and partners' equity at quoted market or fair value, as determined
in good faith by the Liquidation Trustee.
For securities that are publicly traded and for which quotations are
available, the Trust will value the investments based on the closing sale as
of the last day of the fiscal quarter, or in the event of an interim
valuation, as of the date of the valuation. If no sale is reported on such
date, the securities will be valued at the average of the closing bid and
asked prices.
The financial statements include investments valued at $16,348,874 (100% of
total assets) and $12,124,461 (100% of total assets) as of December 31,
2002, and March 31, 2003, respectively, whose values have been estimated by
the Liquidation Trustee. Because of the limited trading market, the estimate
values may differ significantly from the values that would have been used had
a ready market for the investments existed and the difference could be
material. Summarized valuation of investments as of March 31, 2003, follows:
FAIR
COST VALUE
<s> <c> <c>
Tutogen Medical, Inc.
Common Stock $ 16,348,874 $ 12,124,461
____________ ____________
$ 16,348,874 $ 12,124,461
============ ============
ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS
The discussion set forth herein contains certain forward looking statements
with respect to the financial condition, results of operations and business of
the Trust. These forward looking statements are subject to certain risks and
uncertainties, not all of which can be predicted or anticipated. Factors that
may cause actual results to differ materially from those contemplated by the
forward looking statements herein include, but are not limited to, changes in
economic conditions; competitive conditions in the markets in which portfolio
companies conduct their operations, including competition from companies with
substantially greater resources than those of the portfolio companies; and the
results of litigation, which cannot be predicted with certainty. Readers of
this Discussion should not place undue reliance on forward looking statements.
1. Material Changes in Financial Condition
For the first quarter ended March 31, 2003, total Beneficiaries' interest
decreased $2,964,171, due primarily to the decrease in the valuation of common
stock of Tutogen Medical, Inc. with a value of $2.50 per share as of March 31,
2003.
The following portfolio transactions are noted for the quarter ended March
31, 2003 (portfolio companies are herein referred to as the "Company"):
TUTOGEN MEDICAL, INC.
As of March 31, 2003, the Trust was the beneficial owner of 3,674,061 shares
representing approximately 24.24% of the outstanding shares of Tutogen.
The Trustee serves as Chairman of the Board of Directors of Tutogen and,
during the quarter ended March 31, 2003, he continued to assist Tutogen's
efforts to develop new products and markets and to increase its profitability.
The value of the Trust units will ultimately be determined primarily by the
value of the Trust's interest in Tutogen and, accordingly, the Trustee expects
to participate actively in providing guidance and support to Tutogen's
management.
Subsequent to the first quarter of 2003, the Trustee was re-appointed
Chairman of the Board of Tutogen during the company's Annual Meeting held in
April, 2003, in New York.
2. Material Changes in Operations
The Trust currently is under liquidation and not actively considering
additional Portfolio Investments. Therefore, no significant further amount of
income from closing fees and commitment fees is anticipated.
For the quarter ended March 31, 2003, the Trust recorded net loss of
$2,964,171, which was primarily due to a decrease in the closing price of
Tutogen's common stock which was $3.30 as of December 31, 2002, and $2.50 on
March 31, 2003. This valuation may fluctuate significantly due to the limited
trading market for Tutogen stock. The Trust receives no income from the
investments.
ITEM 3: QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
The Trust was formed solely for the purpose of conducting the orderly
liquidation of the assets of the Partnership and does not invest in or hold
instruments to which this Item is applicable.
ITEM 4: CONTROLS AND PROCEDURES
The Trustee, who performs the functions of the Trust's chief executive
officer and chief financial officer, has within the preceding 90 days
evaluated the effectiveness of the Trust's "disclosure controls and
procedures" (as defined in rules 13a-14(c) and 15d-14(c) under the Securities
and Exchange Act of 1934). Based upon that evaluation, the Trustee concluded
that the Trust's disclosure controls and procedures were effective as of the
date of the evaluation. There have been no significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of the evaluation.
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
None other than what has been previously disclosed.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) The exhibit is numbered in accordance with the Exhibit Table of Item 601
of Regulation 5-K.
Exhibit No. Description
_______________ _____________________________________________
99.1 Certification pursuant to Section 906 of
the Sarbanes-Oxley Act
(b) We filed no reports on Form 8-K for the three months ended March 31,
2003.
SIGNATURES
Pursuant to the requirements of Section 13 of 15(d) of the Securities
Exchange Act of 1934, the Registrant had duly caused this report to be signed
on its behalf by the undersigned, there unto duly authorized.
Date: April 25, 2003 CAPITAL PARTNERS II, LTD. LIQUIDATING TRUST
(Registrant)
By: _____/s/__________________________
Thomas W. Pauken
Liquidating Trustee
CERTIFICATION REQUIRED BY RULES 13a-14 AND 15d-14
UNDER THE SECURITIES EXCHANGE ACT OF 1934
I, Thomas W. Pauken, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Capital Partners II,
Ltd. Liquidating Trust;
2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to
make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by
this quarterly report;
3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;
4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:
a) designed such disclosure controls and procedures to ensure that material
information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities,
particularly during the period in which this quarterly report is being
prepared;
b) evaluated the effectiveness of the registrant's disclosure controls and
procedures as of a date within 90days prior to the filing date of this
quarterly report (the "Evaluation Date"); and
c) presented in this quarterly report our conclusions about the effectiveness
of the disclosure controls and procedures based on our evaluation as of the
Evaluation Date;
5. The registrant's other certifying officers and I have disclosed, based on
our most recent evaluation, to the registrant's auditors and the audit
committee of registrant's board of directors (or persons performing the
equivalent function):
a) all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to record,
process, summarize and report financial data and have identified for the
registrant's auditors any material weaknesses in internal controls; and
b) any fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal controls;
and
6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.
Dated: April 25, 2003 _________/s/_______________
Thomas W. Pauken
Liquidating Trustee
Exhibit 99.1
CERTIFICATION OF PERIODIC REPORT
I, Thomas W. Pauken, Liquidating Trustee of Capital Partners II, Ltd.
Liquidating Trust (the "Trust"), certify, pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350, that:
(1) the Quarterly Report on Form 10-Q of the Trust for the quarterly period
ended March 31, 2003 (the "Report") fully complies with the requirements of
Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Trust.
Dated: April 25, 2003 ________/s/________________
Thomas W. Pauken
Liquidating Trustee
A signed original of this written statement required by Section 906 has
been provided to Capital Partners II, Ltd. Liquidating Trust and will be
retained by Capital Partners II, Ltd. Liquidating Trust and furnished to the
Securities and Exchange Commission or its staff upon request.